請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16843
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭彥彬(Yen-Ping Kuo) | |
dc.contributor.author | Chia-Hua Tu | en |
dc.contributor.author | 涂家華 | zh_TW |
dc.date.accessioned | 2021-06-07T23:47:44Z | - |
dc.date.copyright | 2021-02-23 | |
dc.date.issued | 2021 | |
dc.date.submitted | 2021-02-08 | |
dc.identifier.citation | 1. Omura, K., Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma. Int J Clin Oncol, 2014. 19(3): p. 423-30. 2. Wu, H.T., et al., Analysis of the Differentially Expressed Genes Induced by Cisplatin Resistance in Oral Squamous Cell Carcinomas and Their Interaction. Front Genet, 2019. 10: p. 1328. 3. Kim, S.R., et al., Quercetin Inhibits Cell Survival and Metastatic Ability via the EMT-mediated Pathway in Oral Squamous Cell Carcinoma. Molecules, 2020. 25(3). 4. Ariyoshi, Y., et al., Epidemiological study of malignant tumors in the oral and maxillofacial region: survey of member institutions of the Japanese Society of Oral and Maxillofacial Surgeons, 2002. Int J Clin Oncol, 2008. 13(3): p. 220-8. 5. Zaravinos, A., An updated overview of HPV-associated head and neck carcinomas. Oncotarget, 2014. 5(12): p. 3956-69. 6. Markopoulos, A.K., Current aspects on oral squamous cell carcinoma. Open Dent J, 2012. 6: p. 126-30. 7. Ali, H., et al., Oral cancer incidence and survival rates in the Republic of Ireland, 1994-2009. BMC Cancer, 2016. 16(1): p. 950. 8. Silverman, S., Jr., Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc, 2001. 132 Suppl: p. 7s-11s. 9. Pitman, K.T., et al., Cancer of the tongue in patients less than forty. Head Neck, 2000. 22(3): p. 297-302. 10. Myers, J.N., et al., Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol Head Neck Surg, 2000. 122(1): p. 44-51. 11. Shiboski, C.H., S.C. Shiboski, and S. Silverman, Jr., Trends in oral cancer rates in the United States, 1973-1996. Community Dent Oral Epidemiol, 2000. 28(4): p. 249-56. 12. Liu, Y., et al., Quantitative prediction of oral cancer risk in patients with oral leukoplakia. Oncotarget, 2017. 8(28): p. 46057-46064. 13. van der Waal, I., Oral potentially malignant disorders: is malignant transformation predictable and preventable? Med Oral Patol Oral Cir Bucal, 2014. 19(4): p. e386-90. 14. Cervigne, N.K., et al., Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis? Hum Mol Genet, 2014. 23(10): p. 2618-28. 15. Lee, J.J., et al., Carcinoma and dysplasia in oral leukoplakias in Taiwan: prevalence and risk factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2006. 101(4): p. 472-80. 16. Chau, L., et al., Topical agents for oral cancer chemoprevention: A systematic review of the literature. Oral Oncol, 2017. 67: p. 153-159. 17. Wong, T. and D. Wiesenfeld, Oral Cancer. Aust Dent J, 2018. 63 Suppl 1: p. S91-s99. 18. Montero, P.H. and S.G. Patel, Cancer of the oral cavity. Surg Oncol Clin N Am, 2015. 24(3): p. 491-508. 19. Kumar, M., et al., Oral cancer: Etiology and risk factors: A review. J Cancer Res Ther, 2016. 12(2): p. 458-63. 20. Lin, Y.H., et al., Anti-p53 Autoantibody Detection in Automatic Glass Capillary Immunoassay Platform for Screening of Oral Cavity Squamous Cell Carcinoma. Sensors (Basel), 2020. 20(4). 21. Han, S., et al., Co-expression of HIF-1 and TLR3 is associated with poor prognosis in oral squamous cell carcinoma. Int J Clin Exp Pathol, 2020. 13(1): p. 65-72. 22. Warnakulasuriya, S., Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncol, 2010. 46(6): p. 407-10. 23. Matsunaga, T., et al., Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers. Front Pharmacol, 2012. 3: p. 5. 24. Zhong, T., et al., Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss. Biomed Pharmacother, 2015. 69: p. 317-25. 25. Hoffmann, F. and E. Maser, Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev, 2007. 39(1): p. 87-144. 26. Matsunaga, T., S. Shintani, and A. Hara, Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab Pharmacokinet, 2006. 21(1): p. 1-18. 27. Jin, Y. and T.M. Penning, Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol, 2007. 47: p. 263-92. 28. Miller, V.L., et al., Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma. Int J Clin Exp Pathol, 2012. 5(4): p. 278-89. 29. Lin, H.K., et al., Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta- hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids, 2004. 69(13-14): p. 795-801. 30. Fung, K.M., et al., Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer, 2006. 13(1): p. 169-80. 31. Khanna, M., et al., Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid dehydrogenases. J Biol Chem, 1995. 270(34): p. 20162-8. 32. Lin, H.K., et al., Expression and characterization of recombinant type 2 3 alpha- hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol, 1997. 11(13): p. 1971-84. 33. Novotna, R., et al., Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett, 2008. 181(1): p. 1-6. 34. Zhao, S.F., et al., AKR1C1-3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies. Oncol Lett, 2019. 18(5): p. 4515-4522. 35. Guise, C.P., et al., The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res, 2010. 70(4): p. 1573- 84. 36. Sun, S.Q., et al., Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation. Oncotarget, 2016. 7(30): p. 48050- 48058. 37. Xiong, W., et al., Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress. PLoS One, 2014. 9(11): p. e111911. 38. Shiiba, M., et al., Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity. Oncol Rep, 2017. 37(4): p. 2025-2032. 39. Neuwirt, H., et al., Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis. Cell Commun Signal, 2020. 18(1): p. 11. 40. Wang, B., et al., AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. Urol Oncol, 2018. 36(10): p. 472.e11-472.e20. 41. Byrns, M.C., et al., Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over- expression in breast cancer. J Steroid Biochem Mol Biol, 2010. 118(3): p. 177- 87. 42. Jansson, A.K., et al., 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor- positive breast cancer. Cancer Res, 2006. 66(23): p. 11471-7. 43. Suzuki, T., et al., In situ production of sex steroids in human breast carcinoma. Med Mol Morphol, 2007. 40(3): p. 121-7. 44. Milne, S.A. and H.N. Jabbour, Prostaglandin (PG) F(2alpha) receptor expression and signaling in human endometrium: role of PGF(2alpha) in epithelial cell proliferation. J Clin Endocrinol Metab, 2003. 88(4): p. 1825-32. 45. Sales, K.J., et al., Expression, localization, and signaling of prostaglandin F2 alpha receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen- activated protein kinase signaling pathways. J Clin Endocrinol Metab, 2004. 89(2): p. 986-93. 46. Sales, K.J., et al., A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res, 2005. 65(17): p. 7707-16. 47. Matsunaga, T., et al., Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. Chem Biol Interact, 2013. 202(1-3): p. 234-42. 48. Deng, H.B., et al., Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem, 2002. 277(17): p. 15035-43. 49. Chen, Y.J., et al., Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol, 2005. 97(1): p. 110-7. 50. Chen, J., et al., Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol, 2008. 61(6): p. 979-87. 51. Veitch, Z.W., et al., Induction of 1C aldoketoreductases and other drug dose- dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics, 2009. 19(6): p. 477-88. 52. Liu, C., et al., Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res, 2015. 75(7): p. 1413-22. 53. Huebbers, C.U., et al., Upregulation of AKR1C1 and AKR1C3 expression in OPSCC with integrated HPV16 and HPV-negative tumors is an indicator of poor prognosis. Int J Cancer, 2019. 144(10): p. 2465-2477. 54. Shiu, M.N., et al., Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. Br J Cancer, 2000. 82(11): p. 1871-4. 55. Venkatesh, D., et al., Study of salivary arecoline in areca nut chewers. J Oral Maxillofac Pathol, 2018. 22(3): p. 446. 56. Tseng, S.K., et al., Arecoline induced cell cycle arrest, apoptosis, and cytotoxicity to human endothelial cells. Clin Oral Investig, 2012. 16(4): p. 1267-73. 57. Gupta, P.C. and C.S. Ray, Epidemiology of betel quid usage. Ann Acad Med Singapore, 2004. 33(4 Suppl): p. 31-6. 58. Zhang, X. and P.A. Reichart, A review of betel quid chewing, oral cancer and precancer in Mainland China. Oral Oncol, 2007. 43(5): p. 424-30. 59. Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines. IARC Monogr Eval Carcinog Risks Hum, 2004. 85: p. 1-334. 60. Ko, Y.C., et al., Prevalence of betel quid chewing habit in Taiwan and related sociodemographic factors. J Oral Pathol Med, 1992. 21(6): p. 261-4. 61. Hsieh, C.H., et al., Down-regulation of β-catenin and the associated migration ability by Taiwanin C in arecoline and 4-NQO-induced oral cancer cells via GSK- 3β activation. Mol Carcinog, 2017. 56(3): p. 1055-1067. 62. Chandra, J.N., et al., Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models. Neurochem Int, 2008. 52(3): p. 376-83. 63. Maiese, K., et al., Effect of acute and chronic arecoline treatment on cerebral metabolism and blood flow in the conscious rat. Brain Res, 1994. 641(1): p. 65- 75. 64. Saha, I., et al., Ultrastructural and hormonal changes in the pineal-testicular axis following arecoline administration in rats. J Exp Zool A Ecol Genet Physiol, 2007. 307(4): p. 187-98. 65. Wang, S.W., et al., Effects of arecoline on testosterone release in rats. Am J Physiol Endocrinol Metab, 2008. 295(2): p. E497-504. 66. Nair, U., H. Bartsch, and J. Nair, Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis, 2004. 19(4): p. 251-62. 67. Hsieh, Y.P., et al., Arecoline activates latent transforming growth factor β1 via mitochondrial reactive oxygen species in buccal fibroblasts: Suppression by epigallocatechin-3-gallate. J Formos Med Assoc, 2018. 117(6): p. 527-534. 68. Liu, Y.J., et al., The pharmacology, toxicology and potential applications of arecoline: a review. Pharm Biol, 2016. 54(11): p. 2753-2760. 69. Zhou, J., et al., The hepatotoxicity and testicular toxicity induced by arecoline in mice and protective effects of vitamins C and e. Korean J Physiol Pharmacol, 2014. 18(2): p. 143-8. 70. Wei, X., et al., Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats. PLoS One, 2015. 10(4): p. e0120165. 71. Gu, L., et al., Arecoline suppresses epithelial cell viability through the Akt/mTOR signaling pathway via upregulation of PHLPP2. Toxicology, 2019. 419: p. 32-39. 72. Lin, S.H., et al., Arecoline-induced pro-fibrotic proteins in LLC-PK1 cells are dependent on c-Jun N-terminal kinase. Toxicology, 2016. 344-346: p. 53-60. 73. Peng, W., et al., Using the 'target constituent removal combined with bioactivity assay' strategy to investigate the optimum arecoline content in charred areca nut. Sci Rep, 2017. 7: p. 40278. 74. Rehman, A., et al., Areca nut alkaloids induce irreparable DNA damage and senescence in fibroblasts and may create a favourable environment for tumour progression. J Oral Pathol Med, 2016. 45(5): p. 365-72. 75. Huang, J.L., et al., Enhancement of the genotoxicity of benzo[a]pyrene by arecoline through suppression of DNA repair in HEp-2 cells. Toxicol In Vitro, 2016. 33: p. 80-7. 76. Tsai, Y.S., et al., Arecoline, a major alkaloid of areca nut, inhibits p53, represses DNA repair, and triggers DNA damage response in human epithelial cells. Toxicology, 2008. 249(2-3): p. 230-7. 77. Chang, M.C., et al., Areca nut components stimulate ADAM17, IL-1α, PGE2 and 8-isoprostane production in oral keratinocyte: role of reactive oxygen species, EGF and JAK signaling. Oncotarget, 2016. 7(13): p. 16879-94. 78. Thangjam, G.S. and P. Kondaiah, Regulation of oxidative-stress responsive genes by arecoline in human keratinocytes. J Periodontal Res, 2009. 44(5): p. 673-82. 79. Prabhu, R.V., et al., Areca nut and its role in oral submucous fibrosis. J Clin Exp Dent, 2014. 6(5): p. e569-75. 80. Hosein, M., S. Mohiuddin, and N. Fatima, Association Between Grading of Oral Submucous Fibrosis With Frequency and Consumption of Areca Nut and Its Derivatives in a Wide Age Group: A Multi-centric Cross Sectional Study From Karachi, Pakistan. J Cancer Prev, 2015. 20(3): p. 216-22. 81. Utsunomiya, H., et al., Extracellular matrix remodeling in oral submucous fibrosis: its stage-specific modes revealed by immunohistochemistry and in situ hybridization. J Oral Pathol Med, 2005. 34(8): p. 498-507. 82. Tilakaratne, W.M., et al., Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol, 2006. 42(6): p. 561-8. 83. Arakeri, G. and P.A. Brennan, Oral submucous fibrosis: an overview of the aetiology, pathogenesis, classification, and principles of management. Br J Oral Maxillofac Surg, 2013. 51(7): p. 587-93. 84. Yu, C.C., et al., Elevation of S100A4 expression in buccal mucosal fibroblasts by arecoline: involvement in the pathogenesis of oral submucous fibrosis. PLoS One, 2013. 8(1): p. e55122. 85. Lee, S.S., et al., Elevated snail expression mediates tumor progression in areca quid chewing-associated oral squamous cell carcinoma via reactive oxygen species. PLoS One, 2013. 8(7): p. e67985. 86. Radisky, D.C., et al., Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature, 2005. 436(7047): p. 123-7. 87. Wang, T.Y., et al., Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline. Oncotarget, 2016. 7(51): p. 84072-84081. 88. Ho, C.M., et al., ZEB1 as an indicator of tumor recurrence for areca quid chewing-associated oral squamous cell carcinomas. J Oral Pathol Med, 2015. 44(9): p. 693-8. 89. Chang, Y.C., et al., Elevated vimentin expression in buccal mucosal fibroblasts by arecoline in vitro as a possible pathogenesis for oral submucous fibrosis. Oral Oncol, 2002. 38(5): p. 425-30. 90. Lee, S.S., et al., β-catenin expression in areca quid chewing-associated oral squamous cell carcinomas and upregulated by arecoline in human oral epithelial cells. J Formos Med Assoc, 2012. 111(4): p. 194-200. 91. Liu, S.Y., et al., Up-regulation of matrix metalloproteinase-8 by betel quid extract and arecoline and its role in 2D motility. Oral Oncol, 2007. 43(10): p. 1026-33. 92. Anzano, M.A., et al., Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Res, 1982. 42(11): p. 4776-8. 93. Delaney, K., et al., The role of TGF-β1 during skeletal muscle regeneration. Cell Biol Int, 2017. 41(7): p. 706-715. 94. Nickel, J., P. Ten Dijke, and T.D. Mueller, TGF-β family co-receptor function and signaling. Acta Biochim Biophys Sin (Shanghai), 2018. 50(1): p. 12-36. 95. Wrana, J.L., et al., Mechanism of activation of the TGF-beta receptor. Nature, 1994. 370(6488): p. 341-7. 96. Morikawa, M., R. Derynck, and K. Miyazono, TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. Cold Spring Harb Perspect Biol, 2016. 8(5). 97. Nakao, A., et al., TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. Embo j, 1997. 16(17): p. 5353-62. 98. Budi, E.H., D. Duan, and R. Derynck, Transforming Growth Factor-β Receptors and Smads: Regulatory Complexity and Functional Versatility. Trends Cell Biol, 2017. 27(9): p. 658-672. 99. Xie, F., et al., TGF-β signaling in cancer metastasis. Acta Biochim Biophys Sin (Shanghai), 2018. 50(1): p. 121-132. 100. Derynck, R. and Y.E. Zhang, Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 2003. 425(6958): p. 577-84. 101. Zhang, Y.E., Non-Smad Signaling Pathways of the TGF-β Family. Cold Spring Harb Perspect Biol, 2017. 9(2). 102. Heldin, C.H., M. Landström, and A. Moustakas, Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol, 2009. 21(2): p. 166-76. 103. Zhang, Y., P.B. Alexander, and X.F. Wang, TGF-β Family Signaling in the Control of Cell Proliferation and Survival. Cold Spring Harb Perspect Biol, 2017. 9(4). 104. Hu, Z., et al., Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther, 2012. 23(8): p. 871-82. 105. Yin, J.J., et al., TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest, 1999. 103(2): p. 197-206. 106. Kang, Y., et al., A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003. 3(6): p. 537-49. 107. Chen, M.F., et al., Significance of the TGF-β1/IL-6 axis in oral cancer. Clin Sci (Lond), 2012. 122(10): p. 459-72. 108. Diasio, R.B. and B.E. Harris, Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet, 1989. 16(4): p. 215-37. 109. Šuleková, M., et al., A Study of 5-Fluorouracil Desorption from Mesoporous Silica by RP-UHPLC. Molecules, 2019. 24(7). 110. Wang, X., et al., 5-Fluorouracil-cisplatin adducts with potential antitumor activity. J Inorg Biochem, 2003. 94(1-2): p. 186-92. 111. Rich, T.A., R.C. Shepard, and S.T. Mosley, Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol, 2004. 22(11): p. 2214-32. 50 112. Pinedo, H.M. and G.F. Peters, Fluorouracil: biochemistry and pharmacology. J Clin Oncol, 1988. 6(10): p. 1653-64. 113. Dasari, S. and P.B. Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol, 2014. 740: p. 364-78. 114. Thiery, J.P. and J.P. Sleeman, Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol, 2006. 7(2): p. 131-42. 115. Thiery, J.P., et al., Epithelial-mesenchymal transitions in development and disease. Cell, 2009. 139(5): p. 871-90. 116. Lamouille, S., J. Xu, and R. Derynck, Molecular mechanisms of epithelial- mesenchymal transition. Nat Rev Mol Cell Biol, 2014. 15(3): p. 178-96. 117. Nieto, M.A., Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives. Int J Dev Biol, 2009. 53(8-10): p. 1541-7. 118. Nieto, M.A., et al., EMT: 2016. Cell, 2016. 166(1): p. 21-45. 119. Kalluri, R. and R.A. Weinberg, The basics of epithelial-mesenchymal transition. J Clin Invest, 2009. 119(6): p. 1420-8. 120. Mani, S.A., et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 2008. 133(4): p. 704-15. 121. Singh, A. and J. Settleman, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 2010. 29(34): p. 4741-51. 122. Morel, A.P., et al., Generation of breast cancer stem cells through epithelial- mesenchymal transition. PLoS One, 2008. 3(8): p. e2888. 123. Shibue, T. and R.A. Weinberg, EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol, 2017. 14(10): p. 611-629. 124. Lambert, A.W., D.R. Pattabiraman, and R.A. Weinberg, Emerging Biological Principles of Metastasis. Cell, 2017. 168(4): p. 670-691. 125. Olumi, A.F., et al., Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res, 1999. 59(19): p. 5002-11. 126. Kojima, Y., et al., Autocrine TGF-beta and stromal cell-derived factor-1 (SDF- 1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20009-14. 127. Quail, D.F. and J.A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nat Med, 2013. 19(11): p. 1423-37. 128. Terry, S., et al., New insights into the role of EMT in tumor immune escape. Mol Oncol, 2017. 11(7): p. 824-846. 129. Dongre, A. and R.A. Weinberg, New insights into the mechanisms of epithelial- mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol, 2019. 20(2): p. 69-84. 130. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. Br Foreign Med Chir Rev, 1861. 27(53): p. 52-65. 131. Lapidot, T., et al., A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 1994. 367(6464): p. 645-8. 132. Visvader, J.E. and G.J. Lindeman, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer, 2008. 8(10): p. 755-68. 133. Peiris-Pagès, M., et al., Cancer stem cell metabolism. Breast Cancer Res, 2016. 18(1): p. 55. 134. Pattabiraman, D.R. and R.A. Weinberg, Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov, 2014. 13(7): p. 497-512. 135. Hu, J., et al., Cancer stem cell self-renewal as a therapeutic target in human oral cancer. Oncogene, 2019. 38(27): p. 5440-5456. 136. Kreso, A. and J.E. Dick, Evolution of the cancer stem cell model. Cell Stem Cell, 2014. 14(3): p. 275-91. 137. Brooks, M.D., M.L. Burness, and M.S. Wicha, Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell, 2015. 17(3): p. 260-71. 138. Bao, S., et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006. 444(7120): p. 756-60. 139. Li, X., et al., Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst, 2008. 100(9): p. 672-9. 140. Tehranchi, R., et al., Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med, 2010. 363(11): p. 1025-37. 141. Cao, L., et al., Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol, 2011. 11: p. 71. 142. Park, S., et al., Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer. Endocrinology, 2020. 161(2). 143. Naik, P .P ., P .K. Panda, and S.K. Bhutia, Oral Cancer Stem Cells Microenvironment. Adv Exp Med Biol, 2017. 1041: p. 207-233. 144. Pfeiffer, M.J., et al., Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med, 2011. 17(7-8): p. 657-64. 145. Davis, S.J., et al., Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, 2010. 136(12): p. 1260-6. 146. Saxena, M., et al., Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis, 2011. 2(7): p. e179. 147. Gottesman, M.M., T. Fojo, and S.E. Bates, Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer, 2002. 2(1): p. 48-58. 148. Du, B. and J.S. Shim, Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules, 2016. 21(7). 149. Yoshida, T., et al., ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One, 2016. 11(1): p. e0147344. 150. Wilson, M.M., et al., Emerging Mechanisms by which EMT Programs Control Stemness. Trends Cancer, 2020. 6(9): p. 775-780. 151. Hadjimichael, C., et al., Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells, 2015. 7(9): p. 1150-84. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16843 | - |
dc.description.abstract | 依據我國 107 年衛福部統計結果,口腔癌高居國人男性十大癌症中死亡率第 四位。口腔癌的發生主要與吸煙、喝酒和嚼食檳榔有關。檳榔含有的檳榔鹼 (Arecoline)是引起口腔癌的主要致病因子。實驗室先前研究發現,口腔癌病人檢體 中 Aldo-keto-reductase family 1,member C3 (AKR1C3)的蛋白表現量顯著增加,並 且與腫瘤大小和癌症分期呈正相關,患者的五年存活率普遍較低。但其與口腔癌癌 化機轉的關係目前尚未清楚。本研究先將 AKR1C3 的質體與空載體分別送入內生 性 AKR1C3 蛋白表現量低的 Ca922 細胞。根據 transwell migration assay 結果顯示, AKR1C3 表現量高的細胞之移動能力較強。藉由 sphere forming assay 發現過度表 現 AKR1C3 可增加 Ca922 細胞形成聚球體 (sphere) 的能力。此外,AKR1C3 表現 量增加會使上皮-間質轉換 (EMT) markers 中的 N-cadherin 表現量提升,並使 EMT markers 中的 ZO1 和 E-cadherin 表現量降低。同時,AKR1C3 過表現會上調癌幹細 胞相關標誌中 CD133、CD44、KLF4、SOX2 和 Nanog 之表現。以 siRNA 將 AKR1C3 表現量較多的 SAS sphere 進行 AKR1C3 knockdown 後發現,SAS spheres 的形成數 量明顯降低,EMT 中 ZO1 表現上升且同時下調 Snail 和 Twist,而分析其癌幹細胞 相關標誌後發現,CD133、CD44 及 nanog 的蛋白表現皆下降。抗藥性實驗顯示, AKR1C3 表現量高的細胞在加入化療藥物 5-FU 和 cisplatin 作用 72 小時後,分別 於濃度 0.625、1.25 μg/ μl 與 1.25、2.5 μM/ ml 下較對照組都有顯著抗藥效果。綜合 以上結果可知 AKR1C3 表現量高會使細胞發生 EMT 並上調癌幹細胞相關標誌, 進而促進癌細胞的形成細胞 spheres 之能力、生長和移動速度並對 5-FU 和 cisplatin 產生抗性。 | zh_TW |
dc.description.abstract | According to the statistics of the Ministry of Health and Welfare from Taiwan in 2018, oral cancer is the fifth leading cause of cancer-related deaths. The rate of all the cancer-related deaths of oral cancer rose from 9.6% in 2008 to 12.8% in 2018. The main risk factors for the development of oral cancer are including alcohol consumption, smoking and areca nut (AN) chewing. Among these, arecoline which is the main areca nut alkaloid is one of the carcinogens of oral cancer. In previous study, we found Aldo- keto reductase 1 member C3 (AKR1C3) was highly expressed in oral cancer and was related to the tumor sizes, cancer stages and patients’ 5 years survival rates. However, the mechanisms are still not clear. We first transfected AKR1C3 cDNA plasmid and vector into Ca922 cells to establish stable AKR1C3 overexpression clones. We found AKR1C3 overexpression cells has stronger ability of migration through transwell migration assay, increases sphere forming ability, the expressions of stemness marker proteins such as CD133, CD44, KLF4, SOX2 and Nanog. We also found AKR1C3 overexpression increased N-cadherin expression and decreased ZO-1, E-cadherin protein expression. Otherwise, we found knockdown AKR1C3 in SAS sphere by siRNA could decrease the ability of sphere forming, upregulate ZO1 and inhibit the expression of Snail and Twist, down regulate the expression of stemness markers, such as CD133, CD44 and nanog. In addition, we found AKR1C3 overexpression increased resistance to cisplatin and 5-FU compared to controls. In conclusion, our results indicate that overexpression of AKR1C3 make oral cancer cells to be more migrative, growth faster, easier to form spheres, resistant to cisplatin and 5-FU through enhances stemness and EMT. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T23:47:44Z (GMT). No. of bitstreams: 1 U0001-0502202111452400.pdf: 2877105 bytes, checksum: 9b684d05fe523dc94b5338c6a37484d7 (MD5) Previous issue date: 2021 | en |
dc.description.tableofcontents | 誌謝 ................................................................................................................................... i 中文摘要 .......................................................................................................................... ii Abstract............................................................................................................................ iii 目錄 ................................................................................................................................. iv 圖目錄 ............................................................................................................................. vi 附錄目錄 ........................................................................................................................ vii 第一章、研究背景與文獻回顧 ...................................................................................... 1 1.1 口腔癌 (Oralcancer)........................................................................................1 1.2 Aldo-keto reductases family 1, member C3 (AKR1C3) .................................... 2 1.3 檳榔鹼 (Arecoline)........................................................................................... 4 1.4 Transforming growth factor-β1 (TGF-β1)...................................................... 6 1.5 5-Fluorouracil (5-FU) ......................................................................................... 8 1.6 Cisplatin (CDDP) ............................................................................................... 9 1.7 上皮間葉轉化 (Epithelial-Mesenchymal Transition, EMT) ........................... 9 1.8 癌幹細胞 (Cancer Stem Cell) ........................................................................ 10 第二章、研究動機與目的 ............................................................................................ 11 第三章、實驗材料與方法 ............................................................................................ 12 3.1 實驗材料.........................................................................................................12 3.2 實驗方法.........................................................................................................15 3.2.1 細胞繼代培養 (cell culture)................................................................ 15 3.2.2 種細胞與 starvation (Seeding cells and starvation of cells) ................ 15 3.2.3 蛋白質萃取 (Protein quantification)................................................... 15 3.2.4 BCA 蛋白質定量 (BCA protein quantification).................................. 15 3.2.5 西方墨點法 (Western blot).................................................................16 3.2.6 細胞增生速率測試 (Cell proliferation assay) .................................... 17 3.2.7 細胞存活率試驗 (MTT assay) ........................................................... 17 3.2.8 細胞抗藥性試驗 (Drug resistance)..................................................... 17 3.2.9 移動性試驗 (Migration assay)............................................................ 18 3.2.10 侵襲性試驗 (Invasion assay) ............................................................ 18 3.2.11 轉化 (Transformation)....................................................................... 18 3.2.12 抽取質體 (Plasmid extraction).......................................................... 19 3.2.13 質體轉殖與篩選建立穩定過量表現 AKR1C3 的 Ca922 細胞株 (Transfection and establishment of AKR1C3 over-expressed Ca922 clones) 20 3.2.14 細胞聚球體形成試驗 (Sphere forming assay) ................................. 20 3.2.15 AKR1C3 基因 knockdown 實驗 (Knockdown AKR1C3 gene)........ 21 第四章、實驗結果 ........................................................................................................ 22 4.1 SAS spheres 中 AKR1C3 的蛋白表現量較高................................................ 22 4.2 建立 AKR1C3 蛋白表現量高的 Ca922-AKR1C3 細胞與空載體 pcDNA3.1 細胞 ........................................................................................................................ 22 4.3 AKR1C3 overexpression 會增強 Ca922 細胞株的生長速度及細胞之移動能力 ............................................................................................................................ 22 4.4 AKR1C3 表現和口腔癌細胞的 EMT markers 表現相關.............................. 23 4.5 AKR1C3 表現和口腔癌細胞形成聚球體之能力相關 .................................. 23 4.6 AKR1C3 表現和口腔癌細胞的癌幹細胞相關標誌表現相關 ...................... 23 4.7 AKR1C3 表現使細胞對 5-FU 之敏感度明顯下降........................................ 24 4.8 AKR1C3 表現使細胞對 cisplatin 的藥物敏感度顯著性降低....................... 24 第五章、討論與結論 .................................................................................................... 25 圖 .................................................................................................................................... 28 參考文獻 ........................................................................................................................ 41 附錄 ................................................................................................................................ 53 | |
dc.language.iso | zh-TW | |
dc.title | AKR1C3誘導口腔鱗狀上皮細胞癌上皮-間質轉換與幹細胞特性之研究 | zh_TW |
dc.title | AKR1C3 induced epithelial mesenchymal transition and stemness in oral squamous cell carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鄭世榮(Shih-Jung Cheng),周涵怡(Han-Yi Chou) | |
dc.subject.keyword | 口腔癌,醛固酮還原酶家族1成員C3,檳榔鹼,上皮-間質轉換,幹細胞特性,5-氟尿嘧啶,順鉑, | zh_TW |
dc.subject.keyword | oral cancer,AKR1C3,Arecoline,EMT,stemness,5-FU,cisplatin, | en |
dc.relation.page | 55 | |
dc.identifier.doi | 10.6342/NTU202100571 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2021-02-08 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-0502202111452400.pdf 目前未授權公開取用 | 2.81 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。